Skip to content
Head to head

Braveheart Bio vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: BRVE · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

BRVE -31.6%VRTX +6.4%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
BRVEVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price20.39515.02
Change today+5.81%-1.08%
1-year return--+22.0%
Market cap$1.83B$130.58B
52-week range16.70 – 32.00412.27 – 568.67
Valuation
P/E (TTM)-27.8233.14
P/E percentile, own 5-yr range4th99th
P/B3.686.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.9415.32
Net profit (TTM)$-84.03M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-51.65M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership86.1%96.8%
Insider activity (12mo)22 buy / 0 sell28 buy / 22 sell
Short interest (% of float)5.7%1.9%
Analyst consensus100% buy (5)95% buy / 5% hold (21)
Analyst price target$46 (+123%)$624 (+21%)
StockVane view
StockVane Quant RatingC (0)C (68)
Company
Employees306,400
Founded20241989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.